Skip to main content

Table 1 Descriptive statistics for the year 2013

From: Assessing real-world effectiveness of therapies: what is the impact of incretin-based treatments on hospital use for patients with type 2 diabetes?

  

Unmatched sample

Matched sample

   

All

Treated group

Control group

Variables

 

N = 26,244

 N = 2,116

 N = 1,058

 N = 1,058

Health-related

    

Incretin-based treatment

6.09

50.00

100.00

0.00

Hospital use in the previous year

 

16.36

20.35

21.37

19.38

Number of days in hospital

9.69 ± 17.34

10.11 ± 16.06

10.53 ± 14.62

9.66 ± 17.48

At least one GP visit

97.06

96.55

96.30

96.80

Number of GP visits

6.90 ± 5.58

7.72 ± 4.69

7.49 ± 5.02

6.95 ± 4.32

At least one endocrinologist visit

6.54

14.10

13.88

14.31

Number of endocrinologist visits

2.08 ± 1.29

2.19 ± 1.20

2.22 ± 1.08

2.17 ± 1.30

Type of therapy for diabetes

    
 

Monotherapy

59.11

1.95

1.94

1.96

 

Dual therapy

25.79

47.19

48.01

46.40

 

Triple therapy

4.55

34.00

35.06

32.98

 

Insulin therapy

10.55

16.86

14.99

18.67

Polypharmacy

7.00 ± 4.10

7.24 ± 4.09

7.21 ± 4.23

7.28 ± 3.95

Diabetes follow-up (score)

0.55 ± 0.22

0.58 ± 0.21

0.59 ± 0.21

0.57 ± 0.22

Sociodemographic

    

Age

 

71.72 ± 9.35

69.94 ± 9.28

69.84 ± 9.19

70.85 ± 9.37

Female

 

48.12

44.33

48.01

40.80

Living with partner

69.59

69.49

68.55

70.40

Working

 

13.02

14.64

14.06

15.20

100% coverage status

85.08

91.30

89.18

93.33

Income

 

2227.80 ± 1459.41

2254.11 ± 1936.50

2224.07 ± 1016.14

2282.98 ± 2522.46

Patient’s environment

    

Location in a rural area (local level)

5.69

5.39

5.27

5.51

Share of diabetes-related deaths (county level)

2.13 ± 0.68

2.18 ± 0.71

2.16 ± 0.65

2.20 ± 0.77

Density of hospital beds

642.69 ± 160.71

642.63 ± 154.13

645.34 ± 145.95

640.23 ± 162.81

  1. Note. (%) or (mean ± sd)
  2. Among individuals who were experienced the event at leat once (i.e., hospitalization or GP visit or endocrinologist visit)